SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment—finding the right path. Nat Rev Drug Discov 2007; 6: 9911000.
  • 2
    Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 19791998.
  • 3
    Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 10231035.
  • 4
    Locarnini S, Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antivir Ther 2007; 12( Suppl 3): H15H23.
  • 5
    Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004; 200: 15931604.
  • 6
    Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007; 13: 48394847.
  • 7
    Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006; 80: 1109411104.
  • 8
    Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. HEPATOLOGY 2007; 46: 339349.
  • 9
    Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296: 14391443.
  • 10
    Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800807.
  • 11
    Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008; 48: 17691778.
  • 12
    Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. HEPATOLOGY 2006; 43: 563572.
  • 13
    Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61: 12051216.
  • 14
    Morsica G, Bagaglio S, Alagna L, Lodrini C, Gallotta G, Galli L, et al. Mutations in the natural strains of NS3 protease domain of HCV in HIV/HCV coinfected patients under antiretroviral therapy including or not HIV protease inhibitors. In: Hepatology. Boston: Wiley, 2006: 352A.
  • 15
    Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007; 46: 631639.
  • 16
    Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 17671777.
  • 17
    John M, Moore CB, James IR, Mallal SA. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir Ther 2005; 10: 551555.
  • 18
    Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177185.
  • 19
    Sheaffer AK, Mulherin HM, Chen C, Dunaj CV, Lee MS, Franco DL, et al. Characterisation of HCV replicons resistant to inhibitors of NS3 protease activity. In: Proceedings of the 7th International Symposium on Positive Strand RNA viruses; 2004.
  • 20
    Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004; 48: 22602266.
  • 21
    Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, et al. In-vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 1750817514.
  • 22
    Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in-vitro. Antimicrob Agents Chemother 2005; 49: 43054314.
  • 23
    Keeffe EB. Future treatment of chronic hepatitis C. Antivir Ther 2007; 12: 10151025.
  • 24
    He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 2008; 52: 11011110.
  • 25
    Zhou Y, Muh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282: 2261922628.
  • 26
    Zhou Y, Bartels DJ, Hanzelka BL, Muh U, Wei Y, Chu HM, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3–4A serine protease. Antimicrob Agents Chemother 2008; 52: 110120.
  • 27
    Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 2838.
  • 28
    Zeuzem S, Sarrazin C, Wagner F, Rouzier R, Forestier N, Gupta S, et al. Combination therapy with HCV protease inhibitor SCH 503034, plus PEG-Intron in hepatitis C genotype-1 PEG-Intron non-responders: phase 1b results. HEPATOLOGY 2005; 42( Suppl): 1. [Abstract 201].
  • 29
    Seiwert S, Andrews SW, Tan H. Generation and characterisation of HCV replicons with reduced sensitivity to ITMN 191, a macrocyclic inhibitor of NS3/NS4A. National AIDS Treatment Advocacy Project (NATAP) website.
  • 30
    Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008; 370: 237245.
  • 31
    Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor: reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 281: 82058215.
  • 32
    Simmen K, Lenz O, Lin T, Fanning G, Raboisson P, de Kock H, et al. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor TMC435350. In: 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA: November 2–6, 2007. (Abstract 1390).
  • 33
    De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953960.
  • 34
    Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003; 278: 4916449170.
  • 35
    Le Pogam S, Jiang WR, Leveque V, Rajyaguru S, Ma H, Kang H, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006; 351: 349359.
  • 36
    Franciscus A. Hepatitis C treatments in current clinical development. In: Franciscus A, ed. HCV Advocate; 2008.
  • 37
    Gray F, Amphlett L, Bright H, Chambers L, Cheasty A, Fenwick R, et al. GSK625433: A novel and highly potent inhibitor of the HCV NS5B polymerase. In: European Association for the Study of the Liver; April 11–15, 2007; Barcelona, Spain.
  • 38
    Villano S, Raible D, Harper D, Chandra P, Bazisotto L, Bichier G. Phase 1 evaluation of antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with different pegylated interferons in treatment-naive patients with chronic HCV. [Abstract 1302]. HEPATOLOGY 2007; 46( Suppl): 815A.
  • 39
    Cooper CEL, Ghali P, and others. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. In: Proceedings of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston, MA. (Abstract LB11).
  • 40
    Bavisotto L, Wang C, Jacobsen IM, Marcellin P, Zeuzem S, Lawitz EJ, et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. In: Proceedings of the 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2–6, 2007; Boston, MA. (Abstract 49).
  • 41
    Villano S. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment naive HCV-infected patients. [Abstract] HEPATOLOGY 2006; 44: 607A.
  • 42
    McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 16041612.
  • 43
    Howe A, Cheng H, Johann S, Mullen S, Chunduru S, Young D, et al. Identification and characterisation of HCV replicon variants with reduced susceptibility to HCV-796. In: 13th International Meeting on Hepatitis C Virus and Related Viruses; August 2006; Cairns, Australia: 27–31.
  • 44
    Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, et al. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res 2007; 73: 7883.
  • 45
    Lu L, Mo H, Pilot-Matias TJ, Molla A. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759. Antimicrob Agents Chemother 2007; 51: 18891896.
  • 46
    Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, et al. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 2007; 76: 9397.
  • 47
    Chen CM, He Y, Lu L, Lim HB, Tripathi RL, Middleton T, et al. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 2007; 51: 42904296.
  • 48
    Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006; 80: 61466154.
  • 49
    Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 2003; 77: 1322513231.
  • 50
    Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefebvre S, Thauvette L, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005; 280: 3926039267.
  • 51
    Tomei L, Altamura S, Bartholomew L, Bisbocci M, Bailey C, Bosserman M, et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 2004; 78: 938946.
  • 52
    Nguyen TT, Gates AT, Gutshall LL, Johnston VK, Gu B, Duffy KJ, et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother 2003; 47: 35253530.